ophthalmic

Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform

July 25, 2023by Tristen Koerber

7/25/2022, Tampa, FL – Verséa™ Ophthalmics, LLC, a division of Verséa Health, Inc. committed to delivering novel, high-value diagnostic and therapeutic solutions to improve ocular disease, proudly announces the commencement of initial shipments of its T-POC TOTAL IgE Immunoassay and Lateral Flow Readers. The company focuses on delivering innovative Tear-based Point-of-Care (T-POC) testing and biologic solutions that...

Ophthalmics

Verséa™ Ophthalmics at the Hawaii Eye 2023

January 7, 2023by Natasha Svast

Verséa Ophthalmics invites you to attend the Hawaiian Eye 2023 – Disruptive Innovations Symposium on January 16th from 1pm – 2:30pm HST where Dr. Rob Sambursky, our President, will be presenting the latest Eye Care innovations: Novel, Tear-based Point-of-care (POC) diagnostic platform with 2 quantitative tests, Complementary regenerative therapeutics. These innovative solutions will help you...

Ophthalmics

Verséa™ Ophthalmics – proud sponsor of 2022 CEDARS/ASPENS Annual Meeting

December 9, 2022by Natasha Svast

Verséa Ophthalmics is a proud sponsor of this year’s 2022 CEDARS/ASPENS Annual Meeting, taking place today and tomorrow at JW Marriott Camelback, Scottsdale (AZ). CEDARS/ASPENS is a not-for-profit society whose mission is to expand the knowledge of ophthalmic surgery and foster excellence in patient care through clinical experience, peer-to-peer exchange, and practice education. Their mission...

Ophthalmics

Verséa™ Ophthalmics featured at the Eyes On 2023 Corporate Exhibit Hall Interview series

November 29, 2022by Natasha Svast

As part of the corporate exhibit hall interview series at the Eyes On 2023, Verséa Ophthalmics President, Rob Sambursky, MD, was interviewed by Brittany J. McMurren, OD. During the interview, titled “A Deep Dive into New Testing & Therapeutic Innovations” Rob Sambursky, MD presented new testing and therapeutic innovations that Verséa Ophthalmics is bringing to...

Ophthalmics

Verséa™ Ophthalmics President, Dr. Rob Sambursky, interviewed by Ophthalmology Times

November 23, 2022by Natasha Svast

Following the American Academy of Ophthalmology (AAO) 2022 Annual Meeting held in Chicago, Verséa Ophthalmics President, Rob Sambursky, MD, was interviewed by Ophthalmology Times to provide an overview of the company and its products. Dr. Sambursky spoke about BIOVANCE 3L Ocular, a 3-layered decellularized, dehydrated human amniotic membrane (DDhAM) designed for comfort and improved handleability,...

Ophthalmics

Verséa™ Ophthalmics is presenting at the American Academy of Optometry (AAOpt) Meeting 2022

October 25, 2022by Natasha Svast

This week Verséa Ophthalmics team is presenting at the American Academy of Optometry AAOpt 2022 Meeting in San Diego (CA). Visit our booth # 405, where we will be demonstrating our new Tear-Based Point of Care (T-POC) Quantitative Testing Platform that consists of a portable, multifunctional reader and two tear-based quantitative biomarker test kits: –...

Ophthalmics

Verséa™ Ophthalmics is Launching Novel, Point-of-Care, Tear-Based Diagnostic Test Platform at the AAO 2022

September 28, 2022by Natasha Svast

New innovative, rapid, tear-based, POC diagnostic test platform is designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders At this year’s Expo of the American Academy of Ophthalmology AAO 2022 – booth # 1251, Verséa Ophthalmics is launching their comprehensive Product Portfolio and demonstrating...

Corporate

Verséa Searching For Brightest Students and Recent Graduates at the University of Tampa to Join Paid Internship Program

September 21, 2022by Natasha Svast

Verséa is looking for this year’s brightest students and recent graduates to join our Paid Internship Program! Today we are at the University of Tampa searching for ambitious individuals who wish to gain professional experience in Marketing & Business Development at one of the fastest-growing healthcare companies in the U.S. CONTACT US TODAY at 1.813.345.2185...

Ophthalmics

Verséa™ Ophthalmics Signs Exclusive Global Commercialization Agreement With AXIM® Biotechnologies for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions

September 19, 2022by Natasha Svast

“With exclusive global licensing rights to AXIM’s Eye Diagnostics portfolio, Verséa will be introducing a new innovative, rapid, tear-based, POC lab-testing platform designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders.” Verséa Ophthalmics, LLC, a business division of Verséa Holdings, Inc. (“Verséa”), signed exclusive...

Corporate Ophthalmics

Verséa Holdings, Inc. welcomes Rob Sambursky, MD, as President to lead the company’s expansion into the ophthalmic market

August 18, 2022by Natasha Svast

Verséa Holdings, Inc. (“Verséa”) welcomes Rob Sambursky, MD, who joined the company as the President, effective as of August 5, 2022. Dr. Sambursky will support corporate strategy and operations as well as lead the company’s expansion into the ophthalmic market. Verséa recently launched a new business division, Verséa Ophthalmics, with a goal of providing innovative...

Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform

Verséa™ Ophthalmics at the Hawaii Eye 2023

Verséa™ Ophthalmics – proud sponsor of 2022 CEDARS/ASPENS Annual Meeting

Verséa™ Ophthalmics featured at the Eyes On 2023 Corporate Exhibit Hall Interview series

Verséa™ Ophthalmics President, Dr. Rob Sambursky, interviewed by Ophthalmology Times

Verséa™ Ophthalmics is presenting at the American Academy of Optometry (AAOpt) Meeting 2022

Verséa™ Ophthalmics is Launching Novel, Point-of-Care, Tear-Based Diagnostic Test Platform at the AAO 2022

Verséa Searching For Brightest Students and Recent Graduates at the University of Tampa to Join Paid Internship Program

Verséa™ Ophthalmics Signs Exclusive Global Commercialization Agreement With AXIM® Biotechnologies for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions

Verséa Holdings, Inc. welcomes Rob Sambursky, MD, as President to lead the company’s expansion into the ophthalmic market

Subscribe to the Verséa Newsletter

Subscribe to the Verséa Newsletter

Explore Verséa

News